Clinical trials: Pancreas Tumor
Cancer of Pancreas, Cancer of Pelvis
Daily Imaging, Target Identification, and Simulated Computed Tomography-Based Stereotactic Adaptive Radiotherapy Workflow in a Novel Ring Gantry Radiotherapy Device
The investigators propose here to evaluate the feasibility of a novel cone-beam CT (CBCT)-guided online adaptive radiotherapy (ART) workflow on the Halcyon device.
- Conditions
- Cancer of Pancreas, Cancer of Pelvis, Cancer of Abdomen, Cancer of Thorax
- Trial name
- NCT04008537
- Testing
- Ring gantry kV-CBCT combined with linear accelerator
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Washington University School of Medicine
Pancreatic Cyst
Confocal Laser Endomicroscopy as an Imaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions
The study schema is shown in Figure 4. (A) All patients referred to one of the participating academic centers for EUS evaluation of the PCL will be enrolled in the protocol if they satisfy inclusion criteria.
- Trial name
- CLIMB (NCT03492151)
- Where
- 10 sites in United States
- Volunteers
- 500 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Malignant Neoplasm of Head of Pancreas
Billroth II or Roux-en-Y Reconstruction for GJ After PD: Randomized Controlled Trial (PAUDA TRIAL)
The aim of the study is to compare the effect of Roux-en Y reconstruction (study group, DPCDA) versus classical Child reconstruction (DPCUN) in the incidence of VGL in patients for DPC.
- Trial name
- PAUDA (NCT02246205)
- Testing
- Pancreaticoduodenectomy
- Where
- Spain
- Volunteers
- 80 people
- Sponsor
- Hospital Universitari de Bellvitge
Tumors
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
Primary Objective Dose Escalation: To evaluate the safety and tolerability of surufatinib in patients with advanced solid tumors and to determine the maximum tolerable dose (MTD) or recommended phase II dose (RP2D).
- Trial name
- NCT02549937
- Testing
- surufatinib
- Where
- 12 sites in United States, Italy
- Volunteers
- 130 people
- Sponsor
- Hutchmed
Resectable Pancreatic Cancer
Efficacy of Doxycycline on Metakaryote Cell Death in Patients With Resectable Pancreatic Cancer
This is a window-of-opportunity study that examines the efficacy of doxycycline, and FDA-approved oral antibiotic, on metakaryotic (cancer stem cells) in resectable pancreatic cancer following eight weeks of treatment.
- Trial name
- NCT02775695
- Testing
- Doxycycline
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Medical College of Wisconsin
Pancreatic Cancer
Combination Chemotherapy in Treating Patients With Advanced Cancer of the Pancreas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002955
- Testing
- fluorouracil, leucovorin calcium, trimetrexate glucuronate
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Southern California
Pancreatic Cancer
Clinical Study of 177Lu-CTR-FAPI In the Treatment of Patients With Advanced, Metastatic Solid Tumors
This is a single-center, single-arm, open-label clinical study of 177Lu-CTR-FAPI injection in the treatment of patients with advanced, metastatic solid tumors i.e.
- Trial name
- NCT07229768
- Testing
- 177Lu-CTR-FAPI
- Where
- China
- Volunteers
- 4 people
- Sponsor
- Yan Xing
Metastatic Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
Olaparib in Treating Patients With Stage IV Pancreatic Cancer
This phase II trial studies how well olaparib works in treating patients with stage IV pancreatic cancer. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Metastatic Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7
- Trial name
- NCT02677038
- Testing
- Olaparib
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
This phase II trial studies how well giving selumetinib and erlotinib hydrochloride together works in treating patients with locally advanced or metastatic pancreatic cancer that is refractory to chemotherapy.
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT01222689
- Testing
- erlotinib hydrochloride, selumetinib, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Pancreatic Cancer
Proglumide and Chemotherapy for Metastatic Pancreatic Cancer
This is a Phase 2 study with an open labelled lead-in study to approximately treat 30 patients [6 subjects for Lead-in and 24 for Phase 2] enrolled with metastatic pancreatic cancer with combination therapy using standard of care…
- Trial name
- ProGem (NCT05827055)
- Testing
- Gemcitabine, Nab paclitaxel, Proglumide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Georgetown University
Cancer, Solid Tumor
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
This study will evaluate safety, pharmacodynamics and biomarkers of subcutaneous (SC) DK210(EGFR) given as monotherapy and in combination with immunotherapy, chemotherapy or radiation.
- Conditions
- Cancer, Solid Tumor, Colorectal Cancer, Pancreas Cancer
- Trial name
- NCT05704985
- Testing
- DK210 (EGFR), Radiation therapy, Immune checkpoint blockers
- Where
- 7 sites in United States
- Volunteers
- 39 people
- Sponsor
- DEKA Biosciences
Colorectal Adenocarcinoma, Metastatic Cholangiocarcinoma
CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors
This phase I pilot trial studies the side effects of cluster of differentiation 8 (CD8)+ T cells in treating patients with gastrointestinal tumors that have spread to other places in the body.
- Conditions
- Colorectal Adenocarcinoma, Metastatic Cholangiocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Digestive System Carcinoma
- Trial name
- NCT02757391
- Testing
- Adoptive Immunotherapy, Aldesleukin, Cyclophosphamide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Neoplasms
Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms
To evaluate the efficacy and safety of TQB2868 injection combined with anlotinib capsule and chemotherapy in treated patients with Pancreatic Neoplasms
- Trial name
- NCT06767813
- Testing
- TQB2868 injection, Gemcitabine injection, Albumin paclitaxel injection
- Where
- 7 sites in China
- Volunteers
- 80 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Gastric Adenocarcinoma, Esophageal Cancer
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
The primary objective in Phase I is to evaluate the safety and tolerability of sacituzumab govitecan-hziy (SG) as a single agent administered in 21-day treatment cycles in previously treated participants with advanced epithelial…
- Conditions
- Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT01631552
- Testing
- Sacituzumab Govitecan-hziy (SG)
- Where
- 12 sites in United States
- Volunteers
- 515 people
- Sponsor
- Gilead Sciences
Pancreatic Cancer
Gemcitabine With or Without Capecitabine and/or Radiation Therapy or Gemcitabine With or Without Erlotinib in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00634725
- Testing
- capecitabine, erlotinib hydrochloride, gemcitabine hydrochloride
- Where
- 72 sites in France
- Volunteers
- 820 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Pancreatic Neoplasms
Pancreas Volume and Diabetes Status Following Pancreatectomy
This study will enroll 100 patients scheduled to undergo a pancreatectomy. The primary objective is to develop a scoring system using pancreatic volume measured by CT scan and intraoperative measurements of the pancreas…
- Trial name
- NCT02823678
- Testing
- Pancreatectomy
- Volunteers
- 100 people
- Sponsor
- Florida Hospital Tampa Bay Division
Efficacy and Safety
HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer
The purpose of this study is to evaluate the efficacy and safety of HR070803 in Combination With Oxaliplatin plus Tegafur compared to HR070803 in combination with oxaliplatin, 5-fluorouracil/leucovorin (5FU/LV) treatment as…
- Trial name
- NCT06383078
- Testing
- HR070803, Oxaliplatin, Tegafur
- Volunteers
- 120 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Advanced Pancreatic Ductal Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma
This phase I trial tests the safety, side effects, and best dose of FL118 in treating patients with pancreatic ductal adenocarcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts…
- Conditions
- Advanced Pancreatic Ductal Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Refractory Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06206876
- Testing
- Biopsy, Biospecimen Collection, Computed Tomography
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Pancreatic Ductal Adenocarcinoma (mPDAC), Pancreatic Head Tumour
Immunoparalysis After Pancreaticoduodenectomy
By 2030, pancreatic adenocarcinoma could become the second leading cause of cancer-related death in France. To date, Pancreaticoduodenectomy (PD) is the standard treatment for resectable adenocarcinoma of the pancreatic head.
- Conditions
- Pancreatic Ductal Adenocarcinoma (mPDAC), Pancreatic Head Tumour, Pancreatic Fistula
- Trial name
- ImPaHLA (NCT07144917)
- Testing
- mHLA-DR analysis
- Where
- 4 sites in France
- Volunteers
- 100 people
- Sponsor
- Hospices Civils de Lyon
Pancreatic Cancer
Cadonilimab Plus mFOLFIRINOX as Conversion Therapy in LAPC
This is a prospective, single arm, single center, phase II study of cadonilimab plus mFOLFIRINOX as conversion therapy in patients with locally advanced pancreatic cancer.
- Trial name
- NCT06153368
- Testing
- Cadonilimab+mFOLFIRINOX
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.